Press Release Details

INCLINE VILLAGE, Nev., Oct. 29, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period ended September 30, 2020, on Monday, November 9, 2020 after market close.  PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss financial results and provide an update on its progress in monetizing the Company's assets.  A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.

Conference Call Details
We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10149211/db6bb6ea0d.  Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.  Participants may pre-register at any time, including up to and after the call start time.

Those who choose not to pre-register can access the live conference by dialing (833) 685-0901 from the United States or (412) 317-5734 internationally.  The conference ID is 10149211.  Please dial in approximately 10 minutes prior to the start of the call.  A telephone replay will be available for one week following the call and may be accessed by dialing (877) 344-7529 from the United States, (855) 669-9658 from Canada or (412) 317-0088 internationally. The replay passcode is 10149211.

To access the live and subsequently archived webcast of the conference call, go to "Events & Presentations" on the Company's website.  Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma
Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies.  PDL BioPharma was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases.  In 2006, the Company changed its name to PDL BioPharma, Inc.

As of December 2019, PDL ceased making additional strategic transactions and investments and is pursuing a formal process to unlock the value of its portfolio by monetizing its assets and ultimately distributing net proceeds to stockholders in the form of cash or equity.  On August 19, 2020, PDL announced at the Company's 2020 Annual Meeting of Stockholders approval by stockholders for a Plan of Dissolution authorizing the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution.

For more information please visit https://www.pdl.com/

NOTE:  PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-third-quarter-2020-financial-results-and-provide-a-business-update-on-november-9-2020-301162662.html

SOURCE PDL BioPharma, Inc.

LHA Investor Relations, Jody Cain, SVP, (310) 691-7100, jcain@lhai.com